WuXi Biologics Congratulates TESARO for Anti-TIM-3 Antibody IND Submission in the U.S.
SHANGHAI, May 10, 2016 — WuXi Biologics (WuXi), a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today that its partner TESARO submitted an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration.
TESARO, Inc. is an oncology-focused biopharmaceutical company based in Waltham, MA. TSR-022 is a monoclonal antibody drug candidate targeting TIM-3.
“We are pleased to be working with WuXi on our immuno-oncology programs,” said Jeffrey Hanke, Ph.D., Executive Vice President, Research and Development, and Chief Scientific Officer of TESARO. “WuXi’s state-of-the-art, full-service biologics platform enabled us to quickly produce clinical supply of TSR-022 in support of our IND submission.”
“WuXi congratulates our partner for completing this submission. We are very pleased to have completed this critical project from DNA to IND in an expedited manner, which manifested our strong value proposition as a global integrated biologics solution provider,” said Dr. Chris Chen, CEO of WuXi Biologics.
“Congratulations to TESARO on this great progress in the important field of immuno-oncology,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “We are honored to play a role to support innovative partners like TESARO through WuXi’s integrated, open-access R&D services platform, and we wish the program great clinical success.”